The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular ...

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

This clearance is seen as reducing the risk associated with the therapy and is a distinguishing feature compared ... Kostas Biliouris also recognizes the broader implications of RNA editing in ...

RNA from the COVID-19 infection in patients with certain metastatic cancers may be associated with tumor shrinkage, but more ...

Shares of Avidity Biosciences RNA rose more than 12% on Wednesday after the company announced that it is expanding its ...

Development in RNA interference (RNAi) and antisense oligonucleotide (ASO) technologies underpins the growth, as they provide ...

Gene therapy for some diseases, including Duchenne muscular dystrophy (DMD), can be tricky because the needed gene is often ...

Novartis has acquired Kate Therapeutics for up to $1.1 billion, the companies said today, in a deal that expands the buyer’s ...

Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics, a clinical-stage biotech firm focused on RNA therapies, is poised ...

Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire ...

Concurrent DNA and RNA sequencing revealed 15.3% more patients with actionable variants than DNA sequencing alone.